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cost benefit analysis and 3 BIAs. Key assessment criteria that the other studies did not 
meet were consideration of all relevant costs and execution of a sensitivity analysis. 
Of the best quality studies, 3 reported net economic benefits from implementing 
SEDs, at least in the base case analysis. ConClusions: Investment in SEDs gener-
ates economic benefits from savings in managing medical sharps injuries and their 
sequelae. Future economic evaluations need to carefully assess all important and 
pertinent costs to enable well-informed decision making about the implementation 
of SEDs in the health care workplace.
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objeCtives: To compare prices of new drugs between France and the other 
EU4. Methods: Study used IMS MIDAS database for economic data such as prices 
and sales volume and LEEM database (French association of the pharmaceutical 
manufacturers) for the ASMR scale (HAS assessment of the drug’s added value/
innovation). All the products applying for the first time for reimbursement by the 
French Public health insurance between January 2008 and June 2012 were included 
in the study (except those restricted to hospital use in France) and having an ASMR 
rating and an official price in June 2012. Paasche and Laspeyres price-index were 
calculated for drugs with: a) high ASMR, b) ASMR IV, c) ASMR V and d) all drugs. A 
sensitivity analysis was conducted to measure the effect of different weighting 
options. Results: A total of 107 products (245 dosages) were included in this study. 
Fifty-one (48%) have been found available in the community pharmacies of all the 5 
countries. The availability analysis by pair of countries (France + another) is higher: 
94 for Germany, 79 for UK, 71 for Spain and 69 for Italy (Italy often restricts drug’s 
access to hospitals only). French prices are generally equal to or lower than prices 
in the four other markets, which shows a relative price index decrease for France 
since 2008 studies. The only significant exception are UK prices for products ranked 
in France ASMR 1-2-3 (20% less expensive). Prices are regularly and significantly 
higher in Germany than in all other countries. Interestingly, the highest disparities 
in prices occur for the ones ranked as most innovative in France – while ASMR IV 
have surprisingly consistent prices across EU5. ConClusions: European patients 
don’t have consistent access to the same drugs in retail market, and the drugs 
considered innovative in France show a large price index disparity across EU5, with 
UK prices being 20% lower.
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objeCtives: To determine the ability of biosimilars (copies of branded biologics) to 
compete with brand name biologics within the same therapeutic class by analyz-
ing EU-5 G-CSF (Granulocyte-Colony Stimulating Factors) markets and the factors 
affecting the G-CSF biosimilar uptakes, particularly that of biosimilar prices relative 
to reference G-CSFs. Methods: Data on medicine volumes, values and ex-manu-
facturer prices for all G-CSF categories were provided by IMS Health. Volumes were 
calculated in DDD (Defined Daily Doses) and prices in euros per DDD. In the EU-5 
countries biosimilar G-CSFs benefit from a 5-year experience. Data were available 
from 2007 until 2011. Results: There are two G-CSF market profiles: i) countries 
with a high retail market distribution which are the largest G-CSF markets with low 
global G-CSF biosimilar uptakes (5.4% in France and 8.5% in Germany in 2011); ii) 
countries with a dominant hospital channel which are the smallest markets with 
higher G-CSF biosimilar uptakes (12.4% in Spain and 20.4% in the UK). The G-CSF 
biosimilar uptakes depend critically on their market access at a local/regional level. 
The more the decisions are decentralized (hospitals, local purchasing structures) 
the more their uptakes are high (28.3% of the hospital market in France in 2011 
and 20.4% in the UK). The price difference between G-CSF biosimilars and their 
reference plays a marginal role at a global level (+13.3% in the UK and -20.4% in 
France). ConClusions: The competition with G-CSF biosimilars varies signifi-
cantly between EU-5 countries due to distribution channel differences. Currently, 
this competition is not mainly based on prices, but on local political options to 
stimulate tendering between them and other most recently branded products. In 
countries with dominant retail markets, a prerequisite for the success of biosimilar 
G-CSFs is that governments approve their substitution in the same way generics 
are authorized by introducing them case-by-case.
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objeCtives: Since the new Breakthrough Therapy (BT) designation was introduced 
with the new Food and Drug Administration Safety and Innovation Act (FDASIA) 
on 9 July 2012, the FDA has received over 50 requests, and has issued over 20 such 
designations to various candidates in various indications based on preliminary 
evidence that the investigational drugs fulfill a highly unmet medical need where no 
alternatives exist, or demonstrate a significant improvement over existing therapies. 
We have set out to examine the key parameters that characterise a “Breakthrough” 
candidate, and to determine the likelihood of an investigational therapy being 
granted the status. Methods: Using the FDA listing of BT designation statistics, 
publicly available information, as well as IHS Global Insight data, we identified a 
list of currently approved BT candidates between 9 July 2012 and 14 June 2013 and 
determined their preliminary profile characteristics. Results: To date, nearly 75% 
of the designations have been publicly announced by the pharmaceuticals firms 
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objeCtives: To find the association between duration of the process of market-
ing authorization (MA) approval at European Medicines Agency (EMA) and health 
technology assessment (HTA) recommendations in European Union (EU) coun-
tries. Methods: EMA MA timing for new active substances (NASs) during 2007-
2009 were analyzed based on publicly available information. HTA recommendations 
(positive, positive with restrictions, negative, not assessed) issued for the same 
medications in 6 EU countries (SMC, Scotland; AOTM Poland; CVZ, The Netherlands; 
HAS, France; NICE, UK; INFARMED, Portugal) were also analyzed based on public 
information. Hypothesizing that EMA approval process timing might be an indica-
tor of complexity and potential issues in the dossier, the potential for longer EMA 
approval times being associated with less beneficial HTA recommendation was 
investigated. Analyses were performed per country as EMA decisions are centralized 
but HTA recommendations are taken independently by member states. Results: 
A total of 86 NAS were approved by EMA in 2007-2009; mean time of approval was 
460 days (median 423 days). In total, we expected 516 HTA recommendations (86 
drugs assessed by 6 organizations). We found in total 138 positive, 77 positive with 
restrictions, 67 negative recommendations. 234 expected recommendations for 6 
HTA included in this study were not assessed (45,3% of all expected recommenda-
tions). The association between HTA recommendation and approval time (in days) 
was analyzed using Spearman’s rho rank correlation. There was statistically signifi-
cant negative correlation between approval time and HTA recommendation in The 
Netherlands. More time needed for EMA approval was associated with less beneficial 
HTA recommendations. Correlations in other countries were not statistically signifi-
cant. ConClusions: Our research indicates that a longer EMA approval process is 
associated with a less beneficial HTA recommendation in The Netherlands. Further 
research is required whether this indicates that the same issues that cause delays 
at EMA are reconsidered at HTA authorities.
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objeCtives: To assess the impact of an indication extension on pharmaceutical 
prices in 9 markets: Australia, Brazil, France, Germany, Italy, Japan, Spain, Turkey, 
and the UK. Methods: Websites of the EMA and national regulatory agencies 
were surveyed to indentify medicines granted an indication extension between 
2007 and 2013. Eight case studies (bevacizumab, trastuzumab, sunitinib, ivabradine, 
telmisartan, aripiprazole, paliperidone, and omalizumab) were selected based on 
market share and availability across the geographies of interest. The list prices, at 
ex-manufacturer levels, of these eight drugs and those of the medicines belong-
ing to their therapeutic class (at ATC level 3) were collected for the period 2007-13. 
Price movements for these eight medicines were compared to the price evolution 
within their therapeutic class over the period. Results: Based on the selected 
case studies, there is ambivalent synchrony between indication extensions and 
pharmaceutical list price movements in the countries analysed. The data show that 
list prices tend to remain stable following an indication extension. When list prices 
changed subsequent to an indication extension, the movements could not directly 
be linked to the indication extension, as external factors such as a class trend or a 
wider pricing and reimbursement process (e.g. blanket price cuts) could also play a 
role. ConClusions: There is inconclusive evidence that indication extensions lead 
to list price changes in the countries analysed. Moreover, the impact of commercial 
agreements and discounts should be taken into account as secondary indications 
may be subject to separate pricing arrangements (e.g., patient access schemes). As 
such, the selection of the indication for the first marketing-authorisation filing (such 
as a high medical need, niche indication, commanding a premium price) is pivotal 
for the commercial success of a medicine, as its launch price seems unlikely to be 
reviewed following subsequent approvals in broader patient populations.
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objeCtives: To protect health care workers from risk of needlestick injury, preven-
tive safety measures are increasingly mandated in the health care environment, 
which may include the use of safety-engineered medical sharp devices (SEDs) spe-
cifically designed to prevent sharps injuries. We undertook a systematic review of 
the literature to understand the economic impact of replacing conventional sharps 
devices with SEDs. Methods: We conducted searches of electronic databases includ-
ing Embase/MEDLINE, PubMed, CINAHL Plus, HEED, NHS EED, the Cochrane Library, 
ProQuest Nursing and Allied Health Source, and the Tufts CEA Registry. Databases of 
the WHO and HTA agencies, reference lists of identified studies, conference abstract 
books and the internet were also searched. The time horizon covered January 1990 to 
March 2013. Two reviewers independently screened titles and abstracts, applied inclu-
sion criteria to full text papers and extracted data from identified studies according to 
an a priori defined data set. Differences were resolved by consensus. Study quality was 
assessed using a published 10-point checklist. Results: From 19621 records, 21 stud-
ies met the review criteria and were selected. Most studies (16) were budget impact 
analyses (BIAs). Reductions in sharps injuries with SEDs ranging from 12% to 100% 
were reported. Just 4 studies were assessed as providing the best quality evidence: a 
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representative drug dispensing data from ambulatory care). The statistical analy-
sis was performed using SAS Enterprise Guide 4.1. Results: The average price of 
medicines in the NHS market reduced significantly. Until March 2013, the average 
price of generics reduced 59.0% and brands 12.9%. The margins of pharmacies and 
wholesalers decreased in 2012. As a consequence, the outpatient pharmaceutical 
market decreased € 752 million and the NHS expenditure € 468.1 million, between 
2010 and 2012. However, hospital market in 2012 remains at the same level observed 
in 2010. In the first quarter of 2013, outpatient market reduced another 90.3 million 
€ and NHS expenditure € 49.7 M, of which 21% is due to the reduction of distribution 
margins. ConClusions: Even before the MoU, several changes led to a great reduc-
tion of the public expenditure in 2011. This impact worsened after the MoU, with 
direct effects on the reduction of the remuneration of pharmacies and wholesalers. 
Urgent strategies that ensure the access of patients to medicines while preserving 
the sustainability of both the NHS and the network of pharmacies are required, as 
well as policies to monitor the prescribing, dispensing and utilization of medicines 
and concrete changes in the inpatient NHS expenditure.
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objeCtives: Antimicrobial resistance is still a growing health problem which 
increases morbidity, mortality, and health costs and has been associated with inap-
propriate antibiotic use. In Iran antibiotic prescription rates are high in children and 
antibiotics are the most common medication prescribed. Teaching children about 
the different types of microbes and the increasing problems of antibiotic resistance 
with unnecessary and inappropriate use of antibiotics should not only raise aware-
ness in our future generation of antibiotic users but also in the family environment. 
This study aimed to evaluate the effectiveness of the story telling in improving 
children’s knowledge about rational antibiotic use. Methods: Junior (9–11 years) 
school classes were divided into either control or intervention groups for evaluation 
of the story telling. Students were required to complete identical knowledge ques-
tionnaires at three time points (before, immediately after and 4 weeks after teach-
ing), to assess knowledge change and retention. Teaching, using story books which 
provided by National Committee on Rational Drug Use (NCRUD), was given by junior 
school teachers. Results: A total of 164 junior students, 95 were intervention and 
69 control groups, were studied. The junior story telling demonstrated a significant 
improvement in student’s knowledge (34.5% of change) and there was no significant 
decrease in student knowledge observed after a 4 week period. ConClusions: 
Availability of information on the effectiveness of intervention for improving and 
promoting appropriate antibiotics use can facilitate implementation of strategies in 
this field. Regarding the effectiveness of storytelling, it is therefore recommended 
that decison-maker place greater emphasis on the use of such interventions.
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objeCtives: Hospital formularies are usually the gatekeepers for pharmaceutical 
drugs. Typical majority members of hospital formularies are physicians, although 
most of the time the formulary is chaired by a pharmacist. As German hospitals 
are struggling with a difficult economic environment the question arises: what 
kind of decision-making criteria are applied when pharmaceutical drugs should 
be added to the formulary list? Information regarding this topic is scarce due to 
the sensitive topic of decision-making. Only one study (Thürmann et al., 1997) is 
looking into this for Germany. Methods: a total of 588 public, private and ecclesi-
astic hospitals in Germany have been contacted to participate in an online-survey 
regarding the structure of their hospital formulary, roles of members and applied 
decision-making criteria. Results: Thirty-five of 588 hospitals (6%) have finally 
participated and filled out the complete questionnaire. Out of the 35 participants, 
29 were pharmacists (82.9%) and 6 were physicians (17.1%). 34.3% of the hospitals 
have no guidelines for their decision-making and 65.7% of the hospitals with guide-
lines have written (48.6%) or verbal (17.1%) guidelines. Out of these, 78.3% discuss 
decision-making criteria, but only 47.8% talk about the relative importance of the 
discussed decision-making criteria. Budget impact (82.6%), clinical studies (69.6%) 
and price (65.2%) are the most often mentioned decision-making criteria in the 
guidelines. ConClusions: A third of the participating hospitals do not have guide-
lines for their decision-making process and only half of the guidelines discussing 
decision-making criteria also talk about the relative importance. Hospital formular-
ies in Germany do not seem to be transparent in their decision-making process. In 
addition the top 3 decision criteria in the existing guidelines include 2 economical 
criteria which lead to the question of dominance of economical versus medical or 
other criteria. Further research needs to look at the real applied decision-making 
criteria and how much impact economical criteria have on decision-making in 
German hospital formularies.
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objeCtives: In 2011, the AMNOG law changed the price-setting procedure for drugs 
in Germany. Manufacturers are now required to submit a dossier to the Federal 
Joint Committee (GBA) for newly launched or, upon specific request, already market 
products. The GBA decides on the level of additional benefit which impacts the reim-
bursement price negotiations with German sick funds. The objectives of this study 
were thus to: 1) identify ways in which manufacturers can optimize the benefit 
developing the candidates, with investigational oncology drugs representing the 
largest proportion (53%). Orphan diseases make up the second largest group with 
over a third of publicly disclosed BT therapies. In therapeutic areas with already 
available treatment options, such as Hepatitis C Virus infections and advanced mela-
noma, there is still potential for drug candidates to gain BT designation if they can 
be shown to provide an alternative to effectively treat patients that fail to respond 
to the current standard of care. ConClusions: Our investigation has highlighted 
the FDA’s focus on finding breakthrough candidates within oncology as well as 
rare genetic or orphan diseases that do not currently have adequate treatment 
options. Additionally, candidates offering alternative options to non-responders 
have also secured a place on the list, which is likely to grow as increased interest 
and awareness is generated.
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Furet J.1, Marinoni G.2, Ando G.2
1IHS Global, Paris, France, 2IHS, London, UK
objeCtives: From October 2013, some pharmaceutical products will be required 
to undergo a medico-economic evaluation in France. The aim of this study was to 
interview key stakeholders involved in this conceptual change in order to under-
stand how this reform will be implemented and how it will affect market access 
in France. Methods: Primary research was conducted between April and June 
2013 with stakeholders from the French National Authority for Health (HAS), the 
Economic and Public Health Evaluation Commission (CEESP), the Transparency 
Commission (TC) and relevant French ministries. Interviews lasted between 45 
and 75 minutes and focused on the methodology for medico-economic assess-
ment and its implications on the French pharmaceutical pricing and reimbursement 
(P&R) process. Results: Medico-economic evaluation in France will be based on 
cost-utility or cost-effectiveness analyses, depending on whether or not quality 
of life is an important outcome. Cost-utility analyses will rely on QALYs (quality-
adjusted life years), whereas cost-effectiveness analyses will rely on survival. The 
medico-economic assessments will inform pricing negotiations, on the one hand, 
and potentially the development of prescribing guidelines, on the other. Medicines 
will be subjected to a medico-economic assessment based on their level of innova-
tion and/or on their financial impact on the health care budget. ConClusions: 
France is formally introducing the QALY into its P&R system; however, this reform 
will come with a twist on the Anglo-Saxon approach, as there will be no associated 
ICER (incremental cost-effectiveness ratio) above which the medicine will not be 
reimbursed. While there is still some level of uncertainty with regards to the medi-
cines that will be subjected to this assessment (as stakeholders have yet to put a 
quantitative value on a “significant impact” on the health care budget), the direction 
of travel is toward greater pressure on pharmaceutical prices.
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objeCtives: In 2011, we saw the introduction of an evidence-based pricing 
approach to new branded pharmaceuticals in Germany. The process arose from the 
Act of the Reform of the Market for Medicinal Products (AMNOG) and all new drugs 
must undergo clinical benefit assessment by the Federal Joint Committee (GBA) fol-
lowed by price negotiation with the German sick fund (GKV-SV) heads depending on 
whether additional benefit has been demonstrated. A review of the final GBA assess-
ments published to date was undertaken and the aim was to evaluate the implica-
tions for manufacturers considering Germany as a launch country. Methods: The 
GBA and IQWIG websites were searched for AMNOG evaluations performed between 
January 2011 to May 2013. Where appropriate the approach taken in the GBA assess-
ment was compared with that of other HTA groups in Europe. Results: The most 
important consideration for a manufacturer is choosing the right comparator in 
their submission, the core evidence document in this process. A number of drugs 
have been compared to the wrong treatment and subsequently were found to have 
no additional benefit. Some submissions chose the appropriate comparator but 
only for certain subgroups, leading to a reduced overall benefit for the new drug. 
Like most HTA groups, the preference is for mortality, morbidity and side effects 
evidence from head-to-head trials, however GBA appear to give little considera-
tion to quality of life evidence. The review also revealed that GBA make decisions 
that are independent of other HTA bodies and sometimes reject recommendations 
of its own evidence review group, IQWIG. ConClusions: Early engagement with 
GBA to agree an appropriate comparator, patient population and clinical outcome 
measures is very important to improve chances of a positive assessment. However, 
the requirements of the GBA process should be balanced with those of other key 
markets as part of the drug’s global PRA strategy.
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objeCtives: The Memorandum of Understanding signed in May 2011, between the 
Portuguese Government and the International Authorities, increased requirements 
to reduce the public expenditure with medicines. These measures included the 
major change in margins distribution system. This study aims to: 1) describe the 
MoU measures related to medicines; 2) analyze public expenditure and impact of 
distribution margins reductions on medicines public expenditure, due to MoU and 
legislative changes in Portugal. Methods: Descriptive study with updates to the 
MoU and published legislation. Market analysis and simulations were computed 
based on the Pharmacy Sales Information System (a nationwide database with 
